CURE Media Group announces winners of the 2022 MPN Heroes Recognition Program
December 09, 2022 11:00 ET | CURE Media Group
CRANBURY, N.J., Dec. 09, 2022 (GLOBE NEWSWIRE) -- CURE Media Group, the industry-leading multimedia platform devoted to providing cancer updates and research to the more than one million patients,...
IMF_logo_RGB.png
International Myeloma Foundation Named Winner of 2022 Amazon Web Services IMAGINE Grant for Nonprofits
December 01, 2022 08:45 ET | International Myeloma Foundation
STUDIO CITY, Calif., Dec. 01, 2022 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) today announced it has been selected as a winner of the 2022 Amazon Web Services (AWS) IMAGINE...
The Global Community of Hematopoietic Cell Transplantation and Cellular Therapy Specialists Will Gather for the 2023 Tandem Meetings CHICAGO, Nov. 30, 2022 (GLOBE NEWSWIRE) -- The 2023 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® will connect the international community of hematopoietic...
ExCellThera_RGB.png
ExCellThera announces completion of Phase 2 clinical trials for UM171-expanded cell therapy in high-risk blood cancers
November 15, 2022 08:32 ET | ExCellThera
MONTREAL, Nov. 15, 2022 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and rejuvenation, announced today the completion of patient enrollment in its...
ExCellThera_RGB.png
ExCellThera announces 100th patient treated with UM171-expanded cell therapy
November 08, 2022 08:35 ET | ExCellThera
MONTREAL, Nov. 08, 2022 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and rejuvenation, announced today that its proprietary ECT-001 Cell Therapy...
ExCellThera_RGB.png
ExCellThera announces oral presentation of new data on UM171-expanded cell therapy at the ASH Annual Meeting
November 04, 2022 09:30 ET | ExCellThera
MONTREAL, Nov. 04, 2022 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and rejuvenation, announced today that an abstract related to ExCellThera’s...
Mendus AB: Mendus to present multiple abstracts at ASH 2022 including an oral presentation of updated AML survival results from the Phase 2 ADVANCE II trial
November 03, 2022 09:10 ET | Mendus AB
Mendus AB (“Mendus” publ; IMMU.ST, or “the Company”), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that updated results from the Company’s...
Mendus AB: Mendus presenterar flera abstracts på ASH 2022, inklusive en muntlig presentation av uppdaterade AML-överlevnadsresultat från fas 2-studien ADVANCE II
November 03, 2022 09:10 ET | Mendus AB
Mendus AB (“Mendus” publ; IMMU.ST, eller “Bolaget”), ett bioläkemedelsföretag fokuserat på immunterapier som adresserar tumöråterfall, kan idag meddela att uppdaterade resultat från bolagets pågående...
IMF_logo_RGB.png
Scip & Savor for a Cure Fundraiser Benefits the International Myeloma Foundation (IMF) and Family Reach
October 27, 2022 08:45 ET | International Myeloma Foundation
STUDIO CITY, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) today announced the details of the recent fundraising celebration hosted by Fatima Scipione and her...
The AcCELLerate Forum to Focus on Creating a Sustainable Ecosystem of Cell and Gene Therapy
October 24, 2022 12:00 ET | ASTCT
MINNEAPOLIS, Oct. 24, 2022 (GLOBE NEWSWIRE) -- The AcCELLerate Forum, a joint partnership between the American Society for Transplantation and Cellular Therapy (ASTCT™), the Center for International...